Vanda Pharmaceuticals INC

Vanda Pharmaceuticals stockholders approved all proposals at the 2026 annual meeting, including director elections and equity plan amendments.

Vanda Pharmaceuticals announced strong first-quarter 2026 results, driven by Fanapt sales growth and the launch of NEREUS, leading to an increase in full-year revenue guidance.

Vanda Pharmaceuticals has expanded its Board of Directors to seven members with the appointment of veteran biotech analyst Dr. Charles Duncan.

Vanda Pharmaceuticals announced FDA approval for BYSANTI (milsaperidone) to treat bipolar I disorder and schizophrenia in adults, marking a significant psychiatric innovation.

Vanda Pharmaceuticals' Compensation Committee approved 2025 bonuses, 2026 salaries, and new equity awards for its named executive officers.

Vanda Pharmaceuticals announced the FDA again rejected its supplemental New Drug Application for HETLIOZ to treat jet lag disorder, citing insufficient evidence despite acknowledging positive efficacy.

Vanda Pharmaceuticals reported a 3% increase in total revenues for Q1 2026, driven by strong Fanapt sales, while net loss widened due to increased SG&A expenses and lower R&D spending.

Vanda Pharmaceuticals reported a significantly wider net loss in the third quarter of 2025, driven by increased R&D and commercialization expenses, despite strong Fanapt sales growth.

Vanda Pharmaceuticals Inc. reported a significant increase in net loss for the second quarter and first half of 2025, driven by higher research and development and selling, general, and administrative expenses, despite growth in Fanapt sales.

Vanda Pharmaceuticals announces its Q1 2025 financial results, showcasing increased revenue and significant growth in Fanapt prescriptions, while navigating generic competition for Hetlioz and advancing its pipeline.

Vanda Pharmaceuticals' Q3 2024 results show a revenue increase driven by the launch of Fanapt for bipolar disorder and PONVORY for multiple sclerosis, despite ongoing challenges with HETLIOZ generic competition.

Vanda Pharmaceuticals' Q2 2024 results show a complex picture with increased revenues offset by higher expenses and ongoing legal challenges.

Vanda Pharmaceuticals reported a significantly wider net loss in 2025, driven by increased R&D and commercialization expenses, despite new product approvals and growth in Fanapt sales.

Vanda Pharmaceuticals' 2024 10-K filing reveals a year of strategic shifts, including a new acquisition and ongoing patent battles, impacting its financial performance and future outlook.

Vanda Pharmaceuticals acquires PONVORY rights for $100 million while navigating generic competition for HETLIOZ and pursuing regulatory approvals for other pipeline products.

Daniel Patrick McGuire, SVP, GC and Secretary of Vanda Pharmaceuticals, was granted 80,000 restricted stock units.

Phaedra Chrousos, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock through a restricted stock unit award.

Vanda Pharmaceuticals Inc. reports a Form 4 filing detailing a director's acquisition of common stock underlying a restricted stock unit award.

Richard W. Dugan, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock through a restricted stock unit award.

Vanda Pharmaceuticals Inc. Director Anne Sempowski Ward acquired 41,600 shares of common stock through a restricted stock unit award.

Tage Honore, a Director at Vanda Pharmaceuticals Inc., acquired 41,600 shares of common stock underlying a restricted stock unit award.

Vanda Pharmaceuticals announces its 2026 Annual Meeting agenda, including director elections, executive compensation, and a request to increase equity plan shares.

Vanda Pharmaceuticals Inc. has issued a proxy supplement to explain its Board's decision to retain director Phaedra Chrousos despite her failure to receive a majority vote at the 2024 Annual Meeting, while also confirming the expiration of a controversial Rights Agreement.

Vanda Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder meetings and voting on company matters.

Vanda Pharmaceuticals is asking stockholders to approve an amendment to its Amended and Restated 2016 Equity Incentive Plan to increase the share reserve and eliminate its term.

Vanda Pharmaceuticals encourages stockholders to vote FOR all proposals at the virtual Annual Meeting on May 17, 2024.

Vanda Pharmaceuticals encourages stockholders to vote FOR all four proposals at the virtual Annual Meeting on May 17, 2024.

State Street Corporation has reported beneficial ownership of 5.1% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.

BlackRock Portfolio Management LLC has filed a Schedule 13G, reporting beneficial ownership of 4.2% of Vanda Pharmaceuticals Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Vanda Pharmaceuticals Inc. following an internal realignment.

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 5.5% beneficial ownership stake in Vanda Pharmaceuticals Inc. common stock.

Millennium Management LLC and affiliates reported a 2.8% beneficial ownership stake in Vanda Pharmaceuticals Inc. as of December 31, 2025.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a beneficial ownership of 5.3% in Vanda Pharmaceuticals Inc., totaling 3,120,339 shares of common stock.